Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: An immunohistochemical study

Applied Immunohistochemistry and Molecular Morphology

Volumn 17, Issue 4, 2009, Pages 307-311

  Al Abbasi, Dhafer S ^a   Al Janabi, As'Ad A ^a   Al Toriahi, Kaswer M ^a   Jabor, Thekra A ^a   Yasseen, Akeel A ^a,b  

^a UNIVERSITY OF KUFA   (Iraq)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Depleted uranium; Immunostaining; Transitional cell carcinoma; VEGF

Indexed keywords

AVIDIN; BIOTIN; FORMALDEHYDE; PARAFFIN; TUMOR MARKER; URANIUM; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTITIS; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAQ; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSITIONAL CELL CARCINOMA; VEGF GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; ENVIRONMENTAL EXPOSURE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IRAQ; MALE; MIDDLE AGED; NEOPLASM PROTEINS; URANIUM; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68149166867     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181941794     Document Type: Article

References (24)

1. Reuter VE. Pathology of bladder cancer. J Urol. 2006;67:17-18.
2. Oeggerli M, Schraml P, Rfuiz C, et al. E2F3 is the main target gene of the 6p22 amplicon with high specifity for human bladder cancer. Int J Cancer. 2005;117:952-956.
3. Favoni RE, De Cupis A. The role of polypeptide growth factors in human carcinomas. Natl Cancer Inst J. 2000;52:179-206.
4. Jung L, Ba"an BJ, Skopiñska-Różewska E, et al. Clinical immunology VEGF in circulating blood of patients treated with enoxaparine after orthopaedic surgery. Cent Eur J Immunol. 2007;32:61-65.
5. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527-543. (Pubitemid 29426311)
6. Roskoski RJ Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007;356:323-328.
7. Holmes DIR, Zachary I. The VEGF family: angiogenic factors in health and disease. Genome Biol (serial online). 2005;6:209. Available from Biomed Central. Accessed on August 16, 2008.
8. Campbell S, Volpert OV, Ivanovich M, et al. Molecular mediators of angiogenesis in bladder cancer. Cancer Res. 1998;58:1298-1304. (Pubitemid 28183222)
9. Inoue K, Slaton JK, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000;6:4866-4873. (Pubitemid 32110431)
10. Al-Azzawi SN. Depleted uranium radioactive contamination in Iraq: an overview. Global Research. Vol 1. August 2006:4.
11. Hsu SM, Raine L, Fanger H. The use of avidin-biotin peroxidase complex in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580. (Pubitemid 11147380)
12. Eissa S, Shornan S. Tumor markers in diagnosis of tumors of urinary bladder carcinomas. In: Eissa S, Shornan S, eds. Tumor Markers. London: Chapman and Hall; 1999:332-336.
13. Apples SK, Hecht JR, Lewind DN, et al. Immunohistochemical evaluation of K-ras. P53, and HER-2 neu expression in hyper plastic, dysplastic and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol. 1999;30: 123-129.
14. Levy NS, Chung S, Furneaux H, et al. Hypoxic stabilization of VEGF mRNA by the RNA-binding protein HuR. J Biol Chem. 1998;273:6417-6423.
15. Slaton J, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004;171:570-574. (Pubitemid 38090431)
16. Kondo S, Asano M, Suzuki H. Significance of VEGF/vascular permeability factor for solid tumour growth and its inhibition by the antibody. Biochem Biophys Res Commun. 1993;194:1234-1241.
17. Hicklin DJ, Ellis LM. Role of the VEGF pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1-17.
18. Yang CC, Chu KC, Yeh WM. The expression of VEGF in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol. 2004;22:1-6.
19. Santos L, Costa C, Pereira S, et al. Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol. 2003;14:1419-1424. (Pubitemid 37185289)
20. Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer. Prognostic implications and regulation by VEGF-A, C, and D. Clin Cancer Res. 2006;12: 800-806.
21. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997;57:5281-5285. (Pubitemid 27516364)
22. Patel NS, Dobbie MS, Rochester M, et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res. 2006;12:4836-4844. (Pubitemid 44338568)
23. Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, et al. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int. 2002;52:463-469. (Pubitemid 34989304)
24. Jeon SS, Kim TW, Kim W-J. Expression of VEGF in human transitional cell carcinoma. Korean J Urol. 2003;44:256-261.